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Summary
Background Severe infections remain one of the main causes of neonatal deaths worldwide. Possible severe infection 
is diagnosed in young infants (aged 0–59 days) according to the presence of one or more clinical signs. The 
recommended treatment is hospital admission with 7–10 days of injectable antibiotic therapy. In low-income and 
middle-income countries, barriers to hospital care lead to delayed, inadequate, or no treatment for many young 
infants. We aimed to identify eﬀ ective alternative antibiotic regimens to expand treatment options for situations 
where hospital admission is not possible.
Methods We did this randomised, open-label, equivalence trial in four urban hospitals and one rural ﬁ eld site in 
Bangladesh to determine whether two alternative antibiotic regimens with reduced numbers of injectable antibiotics 
combined with oral antibiotics had similar eﬃ  cacy and safety to the standard regimen, which was also used as outpatient 
treatment. We randomly assigned infants who showed at least one clinical sign of severe, but not critical, infection (except 
fast breathing alone), whose parents refused hospital admission, to one of the three treatment regimens. We stratiﬁ ed 
randomisation by study site and age (<7 days or 7–59 days) using computer-generated randomisation sequences. The 
standard treatment was intramuscular procaine benzylpenicillin and gentamicin once per day for 7 days (group A). The 
alternative regimens were intramuscular gentamicin once per day and oral amoxicillin twice per day for 7 days (group B) 
or intramuscular procaine benzylpenicillin and gentamicin once per day for 2 days, then oral amoxicillin twice per day for 
5 days (group C). The primary outcome was treatment failure within 7 days after enrolment. Assessors of treatment 
failure were masked to treatment allocation. Primary analysis was per protocol. We used a prespeciﬁ ed similarity margin 
of 5% to assess equivalence between regimens. This study is registered with ClinicalTrials.gov, number NCT00844337.
Findings Between July 1, 2009, and June 30, 2013, we recruited 2490 young infants into the trial. We assigned 
830 infants to group A, 831 infants to group B, and 829 infants to group C. 2367 (95%) infants fulﬁ lled per-protocol 
criteria. 78 (10%) of 795 per-protocol infants had treatment failure in group A compared with 65 (8%) of 782 infants 
in group B (risk diﬀ erence –1·5%, 95% CI –4·3 to 1·3) and 64 (8%) of 790 infants in group C (–1·7%, –4·5 to 1·1). In 
group A, 14 (2%) infants died before day 15, compared with 12 (2%) infants in group B and 12 (2%) infants in group C. 
Non-fatal relapse rates were similar in all three groups (12 [2%] infants in group A vs 13 [2%] infants in group B 
and 10 [1%] infants in group C).
Interpretation Our results suggest that the two alternative antibiotic regimens for outpatient treatment of clinical signs of 
severe infection in young infants whose parents refused hospital admission are as eﬃ  cacious as the standard regimen. 
This ﬁ nding could increase treatment options in resource-poor settings when referral care is not available or acceptable.
Funding USAID, WHO, Save the Children-US, and Bill & Melinda Gates Foundation.
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Introduction
Although many developing countries have achieved 
substantial decreases in deaths in the post-neonatal 
period and in children aged 1–4 years, neonatal death 
rates have decreased more slowly, with an estimated 
3 million neonatal deaths worldwide every year.1,2 Most of 
these neonatal deaths are in developing countries,3 which 
are characterised by high rates of home delivery by 
unskilled attendants and high rates of infections in 
neonates.4 Up to one in ﬁ ve neonates in developing 
Lancet Glob Health 2015; 
3: e279–87
Published Online
April 2, 2015
http://dx.doi.org/10.1016/
S2214-109X(14)70347-X
See Comment page e245
*The Projahnmo study group is a 
partnership of the Bangladesh 
Ministry of Health and Family 
Welfare, Bangladeshi non-
governmental organisations, and 
the Johns Hopkins University.
International Center for 
Maternal and Newborn 
Health, Department of 
International Health, Johns 
Hopkins Bloomberg School of 
Public Health, Baltimore, MD, 
USA (Prof A H Baqui DrPH, 
D K Mitra PhD, N Begum MA, 
A Mahmud MBBS, 
M H Rahman MBBS, 
M I Moin MA, L C Mullany PhD, 
Prof M Santosham MD, 
Prof R E Black MD); Child Health 
Research Foundation, Dhaka 
Shishu Hospital, Dhaka, 
Bangladesh (Prof S K Saha PhD, 
Prof A S M N U Ahmed FCPS, 
I Quasem MBBS, M Islam BA); 
Bangabandhu Shaikh Mujib 
Medical University, Dhaka, 
Bangladesh 
(Prof M Shahidullah FCPS); 
Department of Paediatrics, 
Hospital for Sick Children and 
University of Toronto, 
Toronto, ON, Canada 
(D E Roth PhD); Shishu Sasthya 
Foundation, Dhaka, 
Bangladesh 
(A K M Samsuzzaman DCH); 
Chittagong Ma O’ Shishu 
Hospital, Chittagong, 
Bangladesh (W Ahmed DCH); 
Institute of Child and Mother 
Health, Matuail, Dhaka, 
Bangladesh 
(Prof S M S B Tabib FCPS); 
Articles
e280 www.thelancet.com/lancetgh   Vol 3   May 2015
countries develop life-threatening infections.5 Several 
preventive interventions against neonatal infections, 
including tetanus toxoid immunisation of pregnant 
women, early and exclusive breastfeeding, use of clean 
delivery practices, and umbilical cord cleansing with 
chlorhexidine, have been identiﬁ ed and incorporated 
into many health-care programmes.4,6–8 However, 
infections remain one of the main causes of neonatal 
deaths worldwide, accounting for roughly a quarter of 
neonatal deaths.2 In settings characterised by high 
neonatal mortality, the proportion of neonatal deaths 
caused by infections has been estimated to be up to 
50%.9–11 Therefore, strategies for timely identiﬁ cation and 
management of infections in neonates and young infants 
(aged 0–59 days) are urgently needed.
WHO recommends that all cases of clinical signs of 
severe infection in young infants (aged 0–59 days) are 
treated in hospital with a 7–10 day course of injectable 
antibiotics—penicillin (or ampicillin) and gentamicin. 
However, in many low-income and middle-income 
countries, this care is often not available, accessible, or 
acceptable to families. Furthermore, the quality of care in 
peripheral facilities is often inadequate because of 
scarcity of trained personnel or necessary supplies.12,13 
These constraints lead to delayed or inadequate treatment 
or no treatment at all for many young infants in low-
income and middle-income countries.
Strategies for community-based management of 
infections in young infants by trained community health 
workers have been developed, assessed, and shown to be 
eﬀ ective.10,14–17 In Bangladesh, our group, Projahnmo, 
showed that identiﬁ cation and treatment of neonates 
with suspected severe infection by trained community 
health workers who used injectable procaine 
benzylpenicillin and gentamicin for 7 days substantially 
reduced neonatal mortality, compared with no care or 
untrained care.10 Although treatment of ill neonates by 
community health workers has been shown to be safe 
and eﬀ ective in low-resource settings, major obstacles 
are associated with large-scale implementation of 
injectable therapy in the community or at ﬁ rst-level 
facilities. First, diﬃ  culties exist in ensuring availability of 
trained health workers and supplies, and in 
implementation of quality assurance for safe injectable 
antibiotic treatment every day for 7–10 days. Second, a 
7–10 day regimen of parenteral antibiotic therapy 
presents challenges to community acceptance and 
compliance. Third, unsupervised use of injections at the 
community level might be unsafe and could increase the 
risk of transmission of HIV, hepatitis, and other viral 
diseases through use of contaminated needles.18 
Therefore, reduction of the number of injections to be 
used is important. Furthermore, the justiﬁ cation for 
7–10 days of parenteral antibiotic therapy has not been 
fully established. 7 days of injectable therapy is perceived 
to be the most eﬃ  cacious regimen in treatment of severe 
infections. However, for some neonates with infections, 
alternative regimens—eg, those that include a 
combination of parenteral and oral therapy or that switch 
to an oral antibiotic after initial treatment with injectable 
antibiotics for 2–3 days—might be equally eﬀ ective, as 
has been shown in older children.19 We aimed to 
determine whether two antibiotic regimens with a 
reduced number of injections are equivalent to the 
standard outpatient course of parenteral antibiotics for 
the treatment of clinical signs of severe infections in 
young infants in Bangladesh, whose parents sought care 
but refused hospital admission.
Methods
Study design
We did this randomised, open-label, equivalence trial at 
the outpatient departments of four urban hospitals and 
one rural ﬁ eld site in Bangladesh. The centres were the 
Dhaka Shishu (children’s) Hospital, Shishu Sasthya 
Hospital, and the Institute of Child and Mother Health 
Hospital in urban Dhaka; Ma O’ Shishu Hospital in 
urban Chittagong; and rural surveillance sites in the 
Sylhet district, Bangladesh. Details of the design and 
implementation of the study have been reported 
previously.20
The institutional review boards of the Bangladesh 
Institute of Child Health, Johns Hopkins Bloomberg 
School of Public Health, London School of Hygiene & 
Tropical Medicine, and WHO reviewed and approved 
this study.
Participants
In the urban hospitals, we screened infants who were 
brought to outpatient departments and enrolled those 
who met the eligibility criteria, whose parents or guardians 
refused hospital admission and consented to the study. In 
the rural site, trained female community health workers 
visited all young infants on days 0, 2, 6, 13, 20, 27, 34, 41, 
48, and 59 after birth to identify infants who were unwell 
based on history and clinical assessments. Community 
health workers referred all unwell infants to one of the 
two designated hospitals within the study area for further 
assessment and care. Research assistants screened young 
infants presenting to the outpatient departments of these 
participating hospitals to identify those who met the age 
and residence criteria. These infants were then screened 
by the study physician for clinical signs of severe infection 
according to the inclusion and exclusion criteria. Infants 
with one or more inclusion criteria and no exclusion 
criteria were clinically eligible. At all sites, we oﬀ ered all 
clinically eligible infants hospital admission or referral to 
another hospital if no hospital bed was available. If the 
infant’s family did not comply with hospital admission or 
referral, the study physician oﬀ ered the option for home 
treatment through study participation.
The inclusion criteria were age 0–59 days, residence 
within a predeﬁ ned geographical area based on feasibility 
of follow-up visits, and the presence of at least one of ﬁ ve 
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clinical signs of severe infection: severe lower chest wall 
indrawing; axillary temperature 38·0°C or more 
(≥100·4°F) conﬁ rmed by a second reading; axillary 
temperature of 35·5°C or less (≤95·9°F) conﬁ rmed by a 
second reading; lethargy, deﬁ ned as movement only on 
stimulation by the examining physician; and history of 
feeding problems, conﬁ rmed by poor suck on 
examination. Infants with fast breathing alone 
(respiratory rate ≥60 breaths per min) were excluded 
because data from previous studies in Bangladesh10 
suggest that this sign alone is not predictive of severe 
illness. Infants with signs of critical illnesses were 
excluded, because outpatient treatment was judged to be 
potentially unsafe for this group. Critical illness was 
deﬁ ned as the presence of any of the following signs: 
unconsciousness; history or presence of convulsions at 
assessment; inability to feed; apnoea; inability to cry; 
cyanosis; bulging fontanelle; major congenital 
malformations; major bleeding; surgical conditions 
needing hospital referral; persistent vomiting after three 
attempts to feed the baby within 30 min; and physician’s 
suspicion of meningitis. Infants were also excluded from 
the study if they weighed less than 1500 g, had been 
admitted to hospital for illness in the past 2 weeks, or 
had previously been included in the study. We obtained 
written informed consent for study participation from 
caregivers of infants who met the eligibility requirements.
Randomisation and masking
We randomly assigned eligible infants to receive either 
the standard antibiotic treatment or one of two alternative 
treatments. The standard treatment was intramuscular 
procaine benzylpenicillin and gentamicin (group A), 
which were given once per day for 7 days. The two 
alternative regimens were intramuscular gentamicin 
once per day and oral amoxicillin twice per day for 7 days 
(group B), and intramuscular procaine benzylpenicillin 
and gentamicin once per day for 2 days, then oral 
amoxicillin twice per day for 5 days (group C).
We randomly assigned infants to one of the three 
treatment regimens, stratiﬁ ed by study site and age 
(<7 days or 7–59 days), using computer-generated 
randomisation sequences (generated by SC, who was not 
involved in the ﬁ eld implementation) with randomly 
permuted block sizes of 6, 9, and 12. We placed the 
allocation sequence for each site and age group in serially 
numbered, sealed, opaque envelopes, and delivered them 
to each site. After we had obtained consent for enrolment, 
Figure: Trial proﬁ le
*Exclusion criteria add up to more than 1840 because some infants had more than one.
75 270 infants screened for eligibility
3171 infants met clinical eligibility criteria 
2490 enrolled and randomised
35 protocol violations 49 protocol violations 39 protocol violations
830 allocated procaine benzylpenicillin 
 and gentamicin (treatment A)
831 allocated gentamicin and amoxicillin 
 (treatment B) 
829 allocated procaine benzylpenicillin and 
 gentamicin, then amoxicillin 
 (treatment C) 
795 included in analysis 782 included in analysis 790 included in analysis
70 259 excluded 
 12 442 outside catchment area
 57 817 had no inclusion criteria
1840 had one or more exclusion criteria* 
 1158 had one or more signs of critical
  illness
 167 weight <1500 g
 104 congenital anomaly
 39 condition needing surgery
 195 hospital admission in past 2 weeks
 36 previous inclusion
 1402 other comorbid condition needing
  hospital admission
5011 infants assessed for exclusion criteria
455 accepted hospital admission 
 53 accepted referral
 173 refused consent
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the study physician selected the next envelope in the 
sequence, and the infant was assigned to the treatment 
corresponding to the allocation code printed within the 
envelope. We did not deem it ethical to give placebo 
injections to such young infants and therefore, we were 
not able to mask the study participants or study 
physicians to treatment group allocation.
Procedures
We selected doses of antibiotics to optimise eﬃ  cacy, safety, 
and feasibility. We used extended-interval (every 24 h) 
gentamicin regimens at doses of 4·0–6·5 mg/kg per 24 h 
and intramuscular procaine benzylpenicillin each day at 
doses of 40 000–50 000 IU/kg.21–23 For amoxicillin, the 
target dose was 75–100 mg/kg per day divided into two 
doses each day.23 All enrolled infants received the ﬁ rst 
doses of the assigned antibiotics and we discharged them 
home after counselling their caregivers on appropriate 
home management. Study physicians made home visits 
every day for the next 7 days to assess the infants to identify 
treatment failure, provide intramuscular injections (if 
allocated), and measure treatment adherence. During 
each visit, doctors taught caregivers of infants allocated to 
oral amoxicillin treatment how to give the oral amoxicillin. 
If an infant vomited within 20 min of oral dosing, the 
caregiver’s instructions were to give another complete 
dose. If the infant vomited within 20 min of the second 
oral dose, the instructions were for caregivers to seek 
medical attention. Additionally, study physicians made 
home visits on days 11 and 15 to identify relapse and death.
The study had internal and external quality assurance 
mechanisms. A clinical supervisor at each study site 
monitored activities with respect to quality and 
consistency of study procedures. A random sample of 
5% of eligibility assessments was repeated by a second 
study physician; the second physician assessor was 
masked to the ﬁ rst physician’s assessment. The 
assessment of the second physician did not routinely 
aﬀ ect study procedures or outcome ascertainment. 
However, if the second physician identiﬁ ed danger signs 
that were missed by the ﬁ rst physician, a supervising 
physician assessed and managed the infant.
If infants who were not admitted to hospital survived, 
and study physicians identiﬁ ed them as meeting the 
criteria for clinical treatment failure on routine follow-up 
visits, we designated them as provisional treatment 
failures, and transported them to the hospital 
accompanied by study personnel. At the hospital, the 
infant received a repeat examination by a second study 
physician. The second physician assessor was masked to 
the treatment allocation and any previous assessments of 
the infant. If the second assessment supported the 
decision of treatment failure, the infant was deemed to 
have conﬁ rmed treatment failure. If the second medical 
assessment disagreed with the ﬁ rst assessment, the 
assessors referred the decision to a supervising physician, 
whose decision was judged to be ﬁ nal. Infants who had 
treatment failure were referred for further hospital care 
according to standard hospital practices.
A technical steering committee and a data safety 
monitoring board provided independent oversight to the 
study. The technical steering committee members and 
independent clinical monitors deployed by the technical 
steering committee made site visits once per year to 
ensure adequate implementation of the study procedures 
and gave feedback to the study team. We used the 
feedback from the technical steering committee to 
further standardise study procedures including clinical 
assessments, as needed.
 Procaine 
benzylpenicillin 
and gentamicin 
(group A, n=830)
Gentamicin and 
amoxicillin 
(group B, n=831)
Procaine 
benzylpenicillin 
and gentamicin, 
then amoxicillin 
(group C, n=829)
Study site
Dhaka Shishu (children’s) Hospital 150 (18%) 150 (18%) 150 (18%)
Shishu Sasthya Hospital 225 (27%) 224 (27%) 225 (27%)
Ma O’ Shishu Hospital 170 (20%) 170 (20%) 170 (21%)
Institute of Child and Mother Health Hospital 117 (14%) 117 (14%) 116 (14%)
Sylhet 168 (20%) 170 (20%) 168 (20%)
Age at enrolment (days)
0–6 86 (10%) 85 (10%) 82 (10%)
7–59 744 (90%) 746 (90%) 747 (90%)
Sex
Male 517 (62%) 516 (62%) 497 (60%)
Female 313 (38%) 315 (38%) 332 (40%)
Weight-for-age Z score at enrolment –1·62 (1·19) –1·62 (1·15) –1·58 (1·18)
Number of signs present
1 508 (61%) 517 (62%) 518 (62%)
2 294 (35%) 279 (34%) 271 (33%)
>2 28 (3%) 35 (4%) 40 (5%)
Fever present
In isolation 179 (22%) 195 (23%) 210 (25%)
With or without another sign 329 (40%) 337 (41%) 369 (45%)
Hypothermia present
In isolation 11 (1%) 10 (1%) 13 (2%)
With or without another sign 18 (2%) 18 (2%) 16 (2%)
Lethargy present
In isolation 1 (<1%) 0 (0%) 2 (<1%)
With or without another sign 17 (2%) 19 (2%) 21 (3%)
Severe chest indrawing present
In isolation 273 (33%) 266 (32%) 252 (30%)
With or without another sign 501 (60%) 500 (60%) 477 (58%)
Poor feeding (suck) present
In isolation 44 (5%) 46 (6%) 41 (5%)
With or without another sign 316 (38%) 306 (37%) 298 (36%)
Local infection present 48 (6%) 50 (6%) 55 (7%)
Mother’s age (years) 24·0 (4·8) 24·3 (4·8) 24·1 (4·6)
Maternal education (years) 5·0 (3·5) 5·1 (3·7) 5·0 (3·6)
Data are n (%) or mean (SD). 
Table 1: Baseline characteristics of all enrolled infants
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Outcomes
The primary outcome was treatment failure in the 7 days 
(up to the day 8 visit) after enrolment. We deﬁ ned 
treatment failure as one or more of the following criteria: 
death at any time before the day 8 assessment; clinical 
deterioration at or before the day 8 assessment based on 
the occurrence of at least one of eight critical signs reported 
by the study physician based on physical examination 
(unconsciousness, convulsions [diagnosed by observation 
or clinical history], inability to feed, apnoea, cyanosis, 
bulging fontanelle, major bleeding, and persistent 
vomiting [deﬁ ned as vomiting after three attempts to feed 
the infant within 30 min, as assessed by study physician]); 
change of antibiotic or addition of another antibiotic by a 
study physician on or before day 8 because of new-onset 
infectious comorbidity (eg, severe omphalitis, bone or 
joint infection, or severe skin or soft tissue infection), or 
serious non-fatal antibiotic-associated adverse event (eg, 
dehydration-associated severe diarrhoea, Stevens-Johnson 
syndrome, anaphylaxis, or acute renal failure); hospital 
admission for any reason at or before the day 8 assessment; 
occurrence of new clinical signs of severe infection at or 
after day 3; presence of at least two of the signs that were 
present on enrolment at day 4 in infants with multiple 
signs at enrolment; presence of the sign on day 4 in infants 
with a single sign on enrolment; recurrence of any one of 
the ﬁ ve inclusion signs on or after day 5; or persistence of 
any one of the ﬁ ve signs of severe infection that was 
present at enrolment on day 8.
The secondary outcomes were the proportions of 
infants who died and of those who had non-fatal relapse, 
deﬁ ned as young infants who were deemed to be cured 
within 7 days but developed any of the clinical signs of 
severe infection after 7 days and within 14 days.
Statistical analysis
We postulated that the alternative therapies would be 
equivalent to the standard therapy and that the treatment 
failure proportion would be 10% in all groups. For each 
comparison (group B vs group A and group C vs group A), 
we planned the analysis to be based on the diﬀ erence in 
the risk of failure between the two treatment groups. We 
used a two-sided 95% CI to assess the similarity of the 
two treatments. We judged the alternative therapies to be 
equivalent to the reference therapy if the upper bound of 
the conﬁ dence interval for the diﬀ erence in treatment 
failure was less than 5%. We used Stata 13.0 software for 
all statistical analysis. We calculated κ to determine 
agreement, which is the standard statistical technique.24
We estimated the sample sizes for this three-armed 
study using Blackwelder’s method.25 We assumed that 
the true failure rate in the standard treatment regimen 
and the alternative regimens would be 10%. We estimated 
that enrolment of 750 evaluable infants in each of the 
three groups (2250 infants in total) would yield 90% 
power to show similarity within 5%, if the true failure 
rates were identical. Based on previous experience in 
similar settings, we allowed for up to 15% loss to 
follow-up, and therefore, aimed to enrol 866 infants to 
each group or 2598 infants in total.
In our primary analysis, we included infants who met 
predeﬁ ned per-protocol criteria based on treatment 
compliance and completeness of clinical follow-up. 
Infants were fully adherent to study treatment if they 
received all doses of scheduled antibiotics on all 7 days or 
by the time of treatment failure (if treatment failure 
occurred), and were not known to have received any other 
antibiotic from a study or non-study physician. We 
deemed infants who were not fully adherent as partly 
adherent if they received all scheduled antibiotics on days 
1–3 or by the time of treatment failure; received at least 
half of the scheduled doses of each antibiotic during days 
4–7, or by the time of treatment failure; were not known to 
have received any non-study injectable antibiotic before 
day 8 assessment; and were not known to have received 
any non-study oral antibiotic on days 1–3. Infants who did 
not fulﬁ l the criteria of being either fully or partly adherent 
were regarded as non-adherent. Infants who received 
scheduled follow-up on all 7 days or up to the time of 
treatment failure (if treatment failure occurred) had 
complete clinical follow-up. Infants had partly complete 
clinical follow-up if they had one or more days of follow-
up missing, but follow-up was completed on assessment 
days 2–4 and at least one of days 5–8, and vital status was 
known on day 8. Infants who did not fulﬁ l the criteria of 
complete or partly complete clinical follow-up had 
incomplete clinical follow-up. The per-protocol analysis 
included infants who had either complete or partly 
complete follow-up and who were either fully or partly 
adherent. We deemed infants with either incomplete 
clinical follow-up or who were non-adherent to be not per 
Procaine 
benzylpenicillin and 
gentamicin (group A, 
n=830)
Gentamicin and 
amoxicillin (group B, 
n=831)
Procaine 
benzylpenicillin and 
gentamicin, then 
amoxicillin (group C, 
n=829)
Clinical follow-up
Complete 791 (95%) 801 (96%) 790 (95%)
Partly complete 16 (2%) 10 (1%) 14 (2%)
Incomplete 23 (3%) 20 (2%) 25 (3%)
Treatment adherence
Completely adherent 784 (94%) 757 (91%) 765 (92%)
Partly adherent 13 (2%) 26 (3%) 30 (4%)
Non-adherent 33 (4%) 48 (6%) 34 (4%)
Per-protocol status*
Per protocol 795 (96%) 782 (94%) 790 (95%)
Not per protocol 35 (4%) 49 (6%) 39 (5%)
Met intention-to-treat criteria† 819 (99%) 821 (99%) 820 (99%)
Data are n (%). *Infants were classiﬁ ed as per protocol if they had complete or partly complete clinical follow-up and 
complete or partly complete treatment adherence. †Received ﬁ rst dose of treatment and were followed up on at least 
one of days 2–8.
Table 2: Per-protocol population
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protocol and we excluded them from the primary per-
protocol analysis. All infants who received the ﬁ rst doses 
of the assigned antibiotics and received at least one follow-
up visit were included in the intention-to-treat analysis.
The data safety monitoring board reviewed the trial 
data every 3 months and met in person once per year. 
The London School of Hygiene & Tropical Medicine was 
the data centre. This study is registered with 
ClinicalTrials.gov, number NCT00844337.
Role of the funding source
The funders of the study had a role in study design, data 
interpretation, and writing of the report. The 
corresponding author had full access to all the data in the 
study and all authors had ﬁ nal responsibility for the 
decision to submit for publication.
Results
Between July 1, 2009, and June 30, 2013, we screened 
75 270 young infants in the outpatient departments of the 
study hospitals (ﬁ gure). We excluded 72 099 (96%) 
infants. 5011 young infants who were from the predeﬁ ned 
catchment areas had one or more inclusion signs, 1158 of 
whom had signs of very severe disease and 682 had other 
exclusion signs. We assigned similar numbers of per-
protocol infants to the three study groups (795 in group A, 
782 infants in group B, and 790 infants in group C).
1984 (80%) enrolled infants were from urban study 
hospitals and 506 (20%) infants were from the rural 
surveillance site. The urban and rural infants presenting 
to the study hospitals were mostly similar, although rural 
infants were younger (aged <7 days: 134 [26%] of 506 rural 
infants vs 253 [10%] of 2490 infants overall), less often 
had multiple presenting signs (65 [13%] of 506 infants vs 
947 [38%] of 2490 infants overall), and were more often 
clinically eligible (713 [11%] of 6339 infants vs 3171 [4%] of 
75 270 infants overall) than were infants from urban sites. 
Almost all of the hypothermia cases were identiﬁ ed in 
the rural hospitals (appendix).
The distribution of enrolled infants was similar across 
treatment groups with respect to age, sex, weight for age at 
enrolment, and mothers’ age and education. Similarly, the 
distributions of presenting signs of enrolled infants were 
also similar across treatment groups (table 1). 2382 (96%) 
infants in all three groups had complete clinical follow-up 
and an additional 40 (2%) infants had partly complete 
clinical follow-up. 2306 (93%) infants were fully adherent 
to the study drugs and another 69 (3%) infants were partly 
Procaine benzylpenicillin and 
gentamicin (group A, n=795)
Gentamicin and amoxicillin 
(group B, n=782)
Procaine benzylpenicillin and 
gentamicin, then amoxicillin 
(group C, n=790)
Treatment failure by day 8 visit 78 (10%) 65 (8%) 64 (8%)
Risk diﬀ erence ·· –1·5% (–4·3 to 1·3) –1·7% (–4·5 to 1·1)
Initial reason for treatment failure
Death 6/78 (8%) 5/65 (8%) 5/64 (8%)
Admitted to hospital 25/78 (32%) 14/65 (22%) 15/64 (23%)
Clinical deterioration 13/78 (17%) 13/65 (20%) 11/64 (17%)
New sign on/after day 3 4/78 (5%) 10/65 (15%) 7/64 (11%)
Persistence of sign(s) at day 4 15/78 (19%) 8/65 (12%) 11/64 (17%)
Recurrence of signs on/after day 5 10/78 (13%) 13/65 (20%) 14/64 (22%)
Persistence at day 8 0/78 1/65 (2%) 0/64
Severe adverse event 3/78 (4%) 0/65 0/64
Antibiotic change because of infectious comorbidity 2/78 (3%) 1/65 (2%) 1/64 (2%)
Admitted to hospital during ﬁ rst week 50 (6%) 34 (4%) 39 (5%)
Risk diﬀ erence ·· –1·9% (–4·2 to 0·3) –1·4% (–3·6 to 0·9)
Died during ﬁ rst week 13 (2%) 9 (1%) 6 (1%)
Risk diﬀ erence ·· –0·5% (–1·6 to 0·7) –0·9% (–1·9 to 0·2)
Died at any time before day 15 follow-up 14 (2%) 12 (2%) 12 (2%)
Risk diﬀ erence ·· –0·2% (–1·5 to 1·0) –0·2% (–1·5 to 1·0)
Treatment successes with follow-up on days 11 or 15 709 700 718
Admitted to hospital during second week* 5 (1%) 2 (<1%) 4 (1%)
Risk diﬀ erence ·· –0·4% (–1·1 to 0·3) –0·1% (–1·0 to 0·7)
Died during second week* 1 (<1%) 1 (<1%) 6 (1%)
Risk diﬀ erence ·· 0·0% (–0·4 to 0·4) 0·7% (–0·0 to 1·4)
Non-fatal relapse during second week* 12 (2%) 13 (2%) 10 (1%)
Risk diﬀ erence ·· 0·2% (–1·2 to 1·5) –0·3% (–1·6 to 1·0)
Data are n (%) or risk diﬀ erence (95% CI). *Percentages calculated from total number of treatment successes with follow-up on days 11 or 15.
Table 3: Primary and secondary treatment outcomes in children in the per-protocol analysis
See Online for appendix
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adherent in all three groups. Most  infants met the per-
protocol criteria (table 2).
Similar to the all enrolled infants, the distribution of 
per-protocol infants with respect to age, sex, weight-for-
age at enrolment, and mothers’ age and education were 
similar across treatment groups. The distributions of 
presenting signs in per-protocol infants were also similar 
across study groups (appendix). 
In group A, 78 (10%) infants had treatment failure, 
compared with 65 (8%) infants in group B and 64 (8%) 
infants in group C (table 3). Risk diﬀ erence between 
groups C and A was –1·5% (95% CI –4·3 to 1·3) and risk 
diﬀ erence between groups B and A was –1·7% (–4·5 to 
1·1). Therefore, the upper bound of both conﬁ dence 
intervals was less than the predeﬁ ned 5% equivalence 
margin. Hospital admission and deaths in the ﬁ rst week 
were slightly more common in group A than in groups B 
and C. Death in the second week was slightly more 
common in group C than in groups A and B, but risk of 
death at any time before the day 15 follow-up was less 
than 2% in all treatment groups. This risk was similar to 
that of infants who opted for hospital admission (5 [2%] 
of 272 infants for whom we had data died during hospital 
admission and another 3 [1%] infants died within 
1 week of discharge). Risk of non-fatal relapse was less 
than 2% in all three groups (table 3). The risk of treatment 
failure among intention-to-treat infants was slightly 
higher than per-protocol infants but similar in all three 
groups (table 4). Non-fatal severe adverse events were 
rare. Three infants in group A, two infants in group B, 
and three infants in group C had severe diarrhoea. We 
detected no cases of Stevens-Johnson syndrome, 
anaphylaxis, or acute renal failure (data not shown).
We included 3719 infants in repeat quality assurance 
assessments at the time of screening. Agreement 
between the two physicians was nearly 100% for all 
inclusion and exclusion signs. The κ values for inclusion 
signs ranged from 0·86 to 1·0. The κ values for all 
exclusion signs were more than 0·8 except for persistent 
vomiting which had a κ value of 0·67 (appendix). 
Discussion
This study is the ﬁ rst outpatient trial of alternative 
antibiotic regimens for infants with clinical signs of 
severe infection (panel). The data show that the 
alternative regimens were eﬃ  cacious and safe for 
outpatient treatment of clinical signs of severe infection 
in young infants whose caregivers did not accept hospital 
Procaine benzylpenicillin and 
gentamicin (group A, n=819)
Gentamicin and amoxicillin 
(group B, n=821)
Procaine benzylpenicillin and 
gentamicin, then amoxicillin 
(group C, n=820)
Treatment failure by day 8 visit 83 (10%) 82 (10%) 70 (9%)
Risk diﬀ erence ·· –0·1% (–3·1 to 2·7) –1·6% (–4·4 to 1·2)
Initial reason for treatment failure
Death 6/83 (7%) 7/82 (9%) 5/70 (7%)
Admitted to hospital 30/83 (36%) 24/82 (29%) 18/70 (26%)
Clinical deterioration 13/83 (16%) 14/82 (17%) 13/70 (19%)
New sign on/after day 3 4/83 (5%) 11/82 (13%) 7/70 (10%)
Persistence of sign(s) at day 4 15/83 (18%) 10/82 (12%) 11/70 (16%)
Recurrence of signs on/after day 5 10/83 (12%) 13/82 (16%) 15/70 (21%)
Persistence at day 8 0/83 1/82 (1%) 0/70
Severe adverse event 3/83 (4%) 1/82 (1%) 0/70
Antibiotic change because of infectious comorbidity 2/83 (2%) 1/82 (1%) 1/70 (1%)
Admitted to hospital during ﬁ rst week 55 (7%) 47 (6%) 44 (5%)
Risk diﬀ erence ·· –1·0% (–3·3% to 1·3%) –1·3% (–3·7 to 1·0)
Died during ﬁ rst week 14 (2%) 11 (1%) 7 (1%)
Risk diﬀ erence ·· –0·4% (–1·6 to 0·8) –0·9% (–1·9 to 0·2)
Died at any time before day 15 follow-up 15 (2%) 14 (2%) 13 (2%)
Risk diﬀ erence ·· –0·1% (–1·4 to 1·1) –0·2% (–1·5 to 1·0)
Treatment successes with follow-up on days 11 or 15 719 714 730
Admitted to hospital during second week* 5 (1%) 2 (<1%) 5 (1%)
Risk diﬀ erence ·· –0·4% (–1·1% to 0·3%) 0·0% (–0·9% to 0·8%)
Died during second week* 1 (<1%) 1 (<1%) 6 (1%)
Risk diﬀ erence ·· 0·0% (–0·4 to 0·4) –0·7% (–0·0 to 1·4)
Non-fatal relapse during second week* 12 (2%) 14 (2%) 11 (2%)
Risk diﬀ erence ·· 0·3 (–1·1 to 1·7) –0·2 (–1·4 to 1·1)
Data are n (%) or risk diﬀ erence (95% CI). *Percentages calculated from total number of treatment successes with follow-up on days 11 or 15.
Table 4: Primary and secondary treatment outcomes in children in the intention-to-treat analysis
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care. Notably, we did not assess the regimens in young 
infants with critical illnesses or in infants with clinical 
signs of severe infection whose caregivers accepted 
hospital admission.
Although the treatment failure rate of about 8–10% 
might seem high, similar rates were reported in an 
earlier community-based study29 that compared three 
antibiotic regimens. To ensure safety of the infants in the 
study, we used highly sensitive criteria (eg, persistence of 
signs on day 4, hospital admission for any reason) to 
assess treatment failure. The risk of death was low, 
similar in all three groups, and similar to that of infants 
who opted for hospital admission.
This trial was individually randomised and we reached 
the desired sample size. The randomisation seemed to 
be eﬀ ective because background characteristics and 
presenting signs were similar in all randomised 
treatment groups. We achieved very high follow-up 
completion and treatment adherence, and only 123 (5%) 
of the 2490 enrolled infants did not meet the per-protocol 
criteria. The trial had robust internal and external 
monitoring and quality assurance methods.30 The low 
loss to follow-up and high treatment adherence, coupled 
with strong monitoring, supports the internal validity of 
the results. We did the study in varied populations (urban 
hospitals where infants were brought by caregivers and 
rural hospitals where cases were identiﬁ ed by trained 
community health workers and referred to hospitals), 
suggesting potential generalisability of the study results.
The trial has some limitations. The design of the trial 
was open-label; masking was not possible for ethical 
reasons. However, treatment failures were assessed by a 
second independent assessor who was masked to 
treatment allocation. The study sample included few 
infants aged 0–6 days, which limits the applicability of 
the results for this age group. We treated clinical signs of 
severe infection, which is a clinical syndrome instead of a 
conﬁ rmed bacterial infection. We believe that this 
approach was appropriate, because the purpose of the 
trial was to develop alternative treatment strategies for 
settings in which hospital care is either not accessible or 
not acceptable to the family. In these settings, laboratory-
based diagnosis of bacterial infection will not generally 
be available. These infants are also the most likely to die 
from clinical signs of severe infection. Even in high-
income settings, early treatment of clinical signs of 
severe infection is often based on clinical suspicion, 
because culture methods are slow and not sensitive. For 
ethical reasons, we recruited infants whose caregivers 
did not accept hospital admission. However, less than 
20% of caregivers accepted hospital admission and the 
case fatality ratio in the infants enrolled in the study was 
similar to that in infants who were admitted to hospital.
In low-resource settings, reliance on a strategy of 
hospital admission for young infants with clinical signs 
of severe infection has several inherent disadvantages. In 
many settings, most young infants who are referred 
might not be able to get to a hospital and might not 
receive treatment, which increases their risk of death.31 
Furthermore, hospital beds are often not available for 
admission of all young infants with clinical signs of 
severe infection. To provide treatment options for such 
settings, and by building on WHO guidelines for 
treatment of pneumonia and previous community-based 
neonate research, we identiﬁ ed and provided evidence of 
the safety and eﬃ  cacy of two antibiotic regimens that can 
be used to treat clinical signs of severe infection in young 
infants as hospital outpatients or in the community. The 
alternative regimens require fewer injections than 
standard outpatient care, which potentially makes them 
more feasible to deliver, more accessible, and more 
acceptable to families. These regimens provide a strategy 
for treatment of young infants with clinical signs of 
severe infection in resource-poor settings with poor 
access to hospital care.
The purpose of the study was not to show that outpatient 
treatment with antibiotic regimens is equivalent to hospital 
care. Instead, we aimed to provide evidence for care of 
young infants for whom hospital care is not accessible or 
acceptable. Safe delivery of these potential new treatment 
Panel: Research in context
Systematic review
In September, 2007, WHO, USAID, and SNL/SCF convened an expert consultation26 on 
community-based approaches to management of neonatal infection to discuss 
programme needs and identify crucial research to accelerate the availability and use of 
safe, eﬀ ective, aﬀ ordable, simple, and feasible community case-management approaches 
for neonatal infection among families with no or little access to facility-based care. The 
meeting objectives were to: review the evidence from recent studies on safety, eﬃ  cacy or 
eﬀ ectiveness, feasibility, acceptability, and use of community-based management 
approaches to neonatal sepsis including community identiﬁ cation of cases, antibiotic 
regimens, care-seeking behaviours, health-system challenges, and ethical issues; identify, 
review, and rank key issues that, if addressed, will lead to expanded access to care and 
enable development of focused short-term programme approaches and a research agenda 
to address the issues not answered by the completed or ongoing studies; and outline and 
design priority research studies that would support the development of programmes to 
increase access to management of sepsis in neonates. We participated in the consultation 
and presented primary data from our own research. The expert panel decided that research 
to assess simpliﬁ ed antibiotic therapies with reduced numbers of injections combined with 
oral antibiotics for the treatment of infections in neonates would be the crucial next step, 
because it would extend access to treatment in settings where hospital care is not 
accessible or acceptable.
Interpretation
To our knowledge, this is the ﬁ rst study to assess the safety and eﬃ  cacy of simpliﬁ ed 
antibiotic regimens for outpatient treatment of clinical signs of severe infection in 
neonates and young infants. Two other studies with similar designs were done 
concurrently, one in Africa27,28 and the other in Pakistan. Our results provide evidence that 
simpliﬁ ed antibiotic regimens with a reduced number of injections are as eﬃ  cacious as 
the standard regimen for outpatient treatment of clinical signs of severe infection in 
young infants. The alternative regimens could provide treatment options for many more 
infants with clinical signs of severe infection who live in resource-poor settings where 
hospital care is not accessible.
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options will need substantial input into training and 
strengthening of primary health-care systems. 
Development of context-speciﬁ c delivery systems will be 
important to ensure availability of trained health workers, 
supply of commodities, and adequate monitoring, 
supervision, and support for primary health-care systems.
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